These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 872138

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cellular kinetics in multiple myeloma. A new approach to staging and treatment.
    Salmon SE, Durie BG.
    Arch Intern Med; 1975 Jan; 135(1):131-8. PubMed ID: 1089396
    [Abstract] [Full Text] [Related]

  • 4. An overview of the status of the nitrosoureas in other tumors.
    Carter SK.
    Cancer Chemother Rep 3; 1973 May; 4(3):35-46. PubMed ID: 4584034
    [No Abstract] [Full Text] [Related]

  • 5. Study of cytosine arabinoside (NSC-63878) synchronization plus vincristine (NSC-67574), prednisone (NSC-10023), and L-asparaginase (NSC-109229) for remission induction in advanced acute leukemia in children.
    Sutow WW, Thomas D, Steuber CP, Pullen J, Vats T, Bryan JH, Morgan SK.
    Cancer Treat Rep; 1976 May; 60(5):591-4. PubMed ID: 991148
    [Abstract] [Full Text] [Related]

  • 6. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D, Bosković D, Radosević N, Elezović I, Tomin D, Gotić M, Antunović P.
    Srp Arh Celok Lek; 1996 May; 124(11-12):292-6. PubMed ID: 9132962
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [New aspects in the clinical course determination and therapy in multiple myeloma].
    Ludwig H, Pietschmann H.
    Acta Med Austriaca; 1979 May; 6(5):255-60. PubMed ID: 555224
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.
    Kuroda Y, Sakai A, Tsuyama N, Katayama Y, Munemasa S, Asaoku H, Okikawa Y, Nakaju N, Mizuno M, Ogawa K, Nishisaka T, Matsui H, Tanaka H, Kimura A.
    Int J Oncol; 2008 Dec; 33(6):1201-13. PubMed ID: 19020753
    [Abstract] [Full Text] [Related]

  • 17. [Personal experience on the chemotherapy of leukemias and hematosarcomas].
    Mathé G, Schneider M, Schwarzenberg L, Cattan A, Amiel JL, Schlumberger JR.
    Acta Genet Med Gemellol (Roma); 1968 Jan; 17(1):245-54. PubMed ID: 4874537
    [No Abstract] [Full Text] [Related]

  • 18. [Current status of treatment for multiple myeloma].
    Tsuchiya J.
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1911-20. PubMed ID: 7184381
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.
    Raje N, Hideshima T, Anderson KC.
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1239-47. PubMed ID: 17020458
    [Abstract] [Full Text] [Related]

  • 20. Synchronization with phase-specific agents in leukemia and correlation with clinical response to chemotherapy.
    Vogler WR, Kremer WB, Knospe WH, Omura GA, Tornyos K.
    Cancer Treat Rep; 1976 Dec; 60(12):1845-59. PubMed ID: 1026339
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.